10-KPeriod: FY1998

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 1998

Filed March 9, 1999For Securities:ABT

Summary

Abbott Laboratories' 1998 10-K filing provides a snapshot of the company's financial position and operational activities as of December 30, 1998. While the provided text is largely navigational and descriptive of the SEC's website rather than the actual financial data of Abbott Laboratories, it indicates the filing date and period end. Investors would typically look to the detailed financial statements, management's discussion and analysis (MD&A), and risk factors sections within the full 10-K report for comprehensive insights. Without the specific financial figures and narrative from the report itself, a deep analysis is not possible. However, the existence of this filing signifies Abbott Laboratories' compliance with SEC reporting requirements. Key areas for investors to scrutinize in the actual report would include revenue trends across its business segments (e.g., pharmaceuticals, diagnostics, nutritionals, medical devices), profitability metrics, balance sheet strength, cash flow generation, and any forward-looking statements or identified risks that could impact future performance.

Key Highlights

  • 1Filing Date: March 8, 1999, for the period ending December 30, 1998.
  • 2Company: Abbott Laboratories (ABT).
  • 3Document Type: 10-K Annual Report.
  • 4Indicates Abbott Laboratories' compliance with annual financial reporting to the SEC.
  • 5The provided content is primarily navigational metadata for the SEC EDGAR database, not the financial report itself.
  • 6Investors should consult the full 10-K for financial statements, MD&A, and risk factor details.

Frequently Asked Questions

This 10-K filing represents Abbott Laboratories' official annual report to the U.S. Securities and Exchange Commission (SEC), providing a comprehensive overview of the company's financial performance, business operations, and risk factors for the fiscal year ending December 30, 1998.

The provided text is a directory listing from the SEC's EDGAR database and contains navigational links and file metadata, not the detailed financial statements or management discussions. To access the actual financial data, you would need to locate and review the .txt or other document files associated with this filing on the SEC's EDGAR system.

Investors should focus on revenue growth across different business segments, profitability trends (gross margin, operating income), balance sheet health (assets, liabilities, equity), cash flow from operations, and any disclosures regarding significant risks, legal proceedings, or management's outlook for future performance.

The filing date indicates that Abbott Laboratories reported its financial results for the fiscal year ending December 30, 1998, approximately two months after the year-end. This is a typical reporting cadence for large public companies.